0.03Open0.03Pre Close0 Volume5 Open Interest10.00Strike Price0.00Turnover96.16%IV39.59%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.0179Delta0.0105Gamma550.17Leverage Ratio-0.0035Theta-0.0002Rho-9.87Eff Leverage0.0019Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet